Research Nester published a report titled “Histoplasmosis Treatment Market: Global Demand Analysis & Opportunity Outlook 2030” which delivers detailed overview of the global histoplasmosis treatment market in terms of market segmentation by type, diagnosis, drug type, route of administration, and by region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
The global histoplasmosis treatment market is estimated to grow at a CAGR of ~9% over the forecast period, i.e., 2022 – 2030. The market is segmented on the basis of route of administration into oral, intravenous, and others, out of which, the intravenous segment is anticipated to hold the notable market share over the forecast period on account of the faster relief action of IV administration. Moreover, growing cases of chronic histoplasmosis requires speedy action, which is easier to attain with IV administration, which is estimated to boost the segment growth.
The global histoplasmosis treatment market is anticipated to grow on the back of increasing incidences of histoplasmosis, supported by the rising cases of immunodeficiency diseases, such as, AIDS. According to the data by the World Health Organization (WHO), around 37.7 million people were suffering from HIV AIDS in 2020. Histoplasmosis is a lung infection caused by a fungus found in the excreta of bats and fowls. The increasing health awareness, and growing investment in development of new drugs, is estimated to boost the market growth.
On the basis of regional analysis, the global histoplasmosis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America region is estimated to gain the largest market share throughout the forecast period, on the back of the high prevalence of histoplasmosis, backed by increasing poultry farming in some regions. According to the data by the Center of Disease Control and Prevalence (CDC), 60% to 90% of the population living in Ohio and Mississippi area were diagnosed of histoplasmosis at least once in their lifetime. Moreover, poor immunity and large geriatric population are some of the factors estimated to boost the regional market growth.
The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.
Poor Immunity and Increasing Prevalence of Histoplasmosis to Fuel the Market Growth
Histoplasmosis affects the people with poor immunity more severely. Rising prevalence of diseases that compromise the immunity, such as, AIDS, is estimated to strengthen the market growth. However, growing circulation of generic drugs is expected to operate as key restraint to the growth of the global histoplasmosis treatment market over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global histoplasmosis treatment market which includes company profiling of Eli Lilly and Company, Hindustan Antibiotics Limited, Sun Pharmaceutical Industries Ltd., Novartis AG, Sanofi- aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc. and others. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global histoplasmosis treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.
Email: [email protected]
U.S. Phone: [+1 646 586 9123]
U.K. Phone: [+44 203 608 591]